Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration

Biomedicine and Pharmacotherapy

Volumn 59, Issue SUPPL. 2, 2005, Pages

  Toi, M ^a   Bando, H ^a   Weich, H A ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Breast cancer; Neovascularization; Soluble vascular endothelial growth factor receptor 1; Vascular endothelial growth factor; Vascular endothelial growth factor receptor 2

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; DNA; ESTROGEN; FULVESTRANT; GONADORELIN AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR; INITIATION FACTOR 4; MESSENGER RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; DNA SYNTHESIS; HORMONAL REGULATION; HUMAN; HYPOTHESIS; MENOPAUSE; MICROENVIRONMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; REVIEW;

EID: 33644592823     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(05)80071-X     Document Type: Article

References (33)

1. Toi M., Matsumoto T., and Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications Lancet Oncol 2 2001 667 673
2. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer Oncologist 5 2000 37 44
3. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors Nat Med 9 2003 669 676
4. Ferrara N., and Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors Nat Med 5 1999 1359 1364
5. Shibuya M. Structure and function of VEGFNEGF-receptor system involved in angiogenesis Cell Struct Funct 26 2001 25 35
6. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor Proc Natl Acad Sci USA 90 1993 10705 10709
7. Hornig C., and Weich H.A. Soluble VEGF receptors Angiogenesis 3 1999 33 39
8. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR Biochem Biophys Res Commun 226 1996 324 328
9. Lamszus K., Ulbricht U., Matschke J., Brockmann M.A., Fillbrandt R., and Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A Clin Cancer Res 9 2003 1399 1405
10. Toi M., Bando H., Ogawa T., Muta M., Hornig C., and Weich H.A. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer Int J Cancer 98 2002 14 18
11. Sako A., Kitayama J., Koyama H., Ueno H., Uchida H., and Hamada H. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer Cancer Res 64 2004 3624 3628
12. Goldman C.K., Kendall R.L., Cabrera G., Soroceanu L., Heike Y., and Gillespie G.Y. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate Proc Natl Acad Sci USA 95 1998 8795 8800
13. Takayama K., Ueno H., Nakanishi Y., Sakamoto T., Inoue K., and Shimizu K. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ Cancer Res 60 2000 2169 2177
14. Hyder S.M., Nawaz Z., Chiappetta C., and Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor Cancer Res 60 2000 3183 3190
15. Stewart R.J., Panigrahy D., Flynn E., and Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts J Urol 165 2001 688 693
16. Garvin S., and Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo Cancer Res 63 2003 8742 8748
17. Nakamura J., Savinov A., Lu Q., and Brodie A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a) anthracene-induced rat mammary tumors Endocrinology 137 1996 5589 55896
18. Scott P.A., Smith K., Poulsom R., De Benedetti A., Bicknell R., and Harris A.L. Differential expression of vascular endothelial growth factor mRNA vs. protein isoform expression in human breast cancer and relationship to eIF-4E Br J Cancer 77 1998 2120 2128
19. Stoner M., Wormke M., Saville B., Samudio I., Qin C., and Abdelrahim M. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins Oncogene 23 2004 1052 1063
20. Buteau-Lozano H., Ancelin M., Lardeux B., Milanini J., and Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta Cancer Res 62 2002 4977 4984
21. Elkin M., Orgel A., and Kleinman H.K. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1 J Natl Cancer Inst 96 2004 875 878
22. Bogin L., and Degani H. Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer Cancer Res 62 2002 1948 1951
23. Seo K.H., Lee H.S., Jung B., Ko H.M., Choi J.H., and Park SJ. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation Cancer Res 64 2004 6482 6488
24. Guo P., Fang Q., Tao H.Q., Schafer C.A., Fenton B.M., and Ding I. Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo Cancer Res 63 2003 4684 4691
25. Dowsett M., Detre S., Rowlands M., and Grimshaw R. Oestrogen formation in breast: clinical and biological importance J Endocrinol 150 1996 S59 S63
26. Suzuki T., Moriya T., Ishida T., Ohuchi N., and Sasano H. Intracrine mechanism of estrogen synthesis in breast cancer Biomed Pharmacother 57 2003 460 462
27. Jakesz R., Hausmaninger H., Kubista E., Gnant M., Menzel C., and Bauernhofer T. Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5 J Clin Oncol 20 2002 4621 4627
28. Geisler J., Detre S., Berntsen H., Ottestad L., Lindtjorn B., and Dowsett M. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer Clin Cancer Res 7 2001 1230 1236
29. Howell A., and Dowsett M. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens Breast Cancer Res 6 2004 269 274
30. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., and Piccart M.J. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802
31. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., and Delozier T. Intergroup Exemestane Study. A randomized trial of exemestane after 2-3 years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
32. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810
33. Harris A.L., Reusch P., Barleon B., Hang C., Dobbs N., and Marme D. Soluble Tie2 and Fltl extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy Clin Cancer Res 7 2001 1992 1997